For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Beam Therapeutics Inc. (BEAM) been one of those stocks this ...

These factors contribute to the Buy rating as Beam Therapeutics continues to lead innovation in its field. In another report released on January 7, Bernstein also upgraded the stock to a Buy with ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

Yanan Zhu, an analyst from Wells Fargo, reiterated the Buy rating on Beam Therapeutics (BEAM – Research Report). The associated price target remains the same with $75.00. Discover outperforming ...

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the ...